Clinical Trial Update: Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of gemcitabine, docetaxel, and filgrastim in patients with recurrent or persistent leiomyosarcoma or soft tissue sarcom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Gemzar (gemcitabine)
• Neupogen (Filgrastim)
• Taxotere (docetaxel)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Ovarian Cancer, Sarcoma | Phase 2 | Status: COMPLETED